Scheduled maintenance This site will be offline from 13:30 to 15:00 CEST on Monday, 21 October 2024 in order to be moved to a new infrastructure. We apologise for the inconvenience. Please check the Slack channel #dc-system-status for updates. The development team can be contacted at datacentre@scilifelab.se if you have any question.

Evaluation of Production Lots of a Rapid Point-of-Care Lateral Flow Serological Test Intended for Identification of IgM and IgG against the N-Terminal Part of the Spike Protein (S1) of SARS-CoV-2.

Hoffman T, Kolstad L, Rönnberg B, Lundkvist Å

Viruses 13 (6) - [2021-05-31; online 2021-05-31]

The potential of rapid point-of-care (POC) tests has been subject of doubt due to an eventual risk of production errors. The aim was therefore to evaluate the two separate production lots of a commercial POC lateral flow test, intended for the detection of IgM and IgG against the SARS-CoV-2 spike protein (S1). Control samples consisted of serum from individuals with confirmed SARS-CoV-2 infection and pre-COVID-19 negative sera gathered from a biobank. The presence of anti-S1 IgM/IgG in the sera was verified by an in-house Luminex-based serological assay (COVID-19 SIA). One hundred samples were verified as positive for anti-S1 IgG and 74 for anti-S1 IgM. Two hundred samples were verified as negative for anti-S1 IgM/IgG. For the two lots of the POC-test, the sensitivities were 93.2% and 87.8% for IgM and 93.0% and 100% for IgG. The specificities were 100% for IgM and 99.5% for IgG. The positive predictive value was 100% for IgM and 98.9% and 99.0% for IgG. The negative predictive value was 97.6% and 95.7% for IgM, and 96.6% and 100% for IgG. The evaluated POC-test is suitable to assess anti-SARS-CoV-2 S1 IgM and IgG, as a measure of previous virus exposure on an individual level. The external validation of separate lots of rapid POC-tests is encouraged to ensure high sensitivity before market introduction.

Category: Biochemistry

Category: Health

Funder: H2020

Funder: KAW/SciLifeLab National COVID program

Funder: VR

Research Area: High-throughput and high-content serology

Type: Journal article

PubMed 34072890

DOI 10.3390/v13061043

Crossref 10.3390/v13061043

pii: v13061043


Publications 9.5.1-pretest